Zydus gets DCGI nod for conducting phase-3 clinical trials of ZyCoV-D

Company to initiate trials with around 30,000 volunteers

Paving the way for a timely roll-out of another indigenous Covid-19 vaccine, the Drugs Controller General of India (DCGI) has approved phase 3 clinical trials of Ahmedabad-based Cadila Healthcare’s ZyCov-D.

With this, the firm, also known as Zydus Cadila, will initiate phase 3 clinical trials on around 30,000 volunteers. Depending on the progress of researches and outcomes, Zydus is hoping to launch the vaccine in the first quarter of the next financial year.

According to Zydus Group Chairman Pankaj Patel, the launch of such trials will determine the efficacy of the vaccine.

The company had applied for permission with the DCGI after the